Effects of Agomelatine Tablets Combined with Paroxetine Hydrochloride on SOD and BDNF Levels in Patients with Depression and Insomnia Disorder
Objective To analyze the effect of agomelatine tablets combined with paroxetine hydrochloride on the levels of SOD and BDNF in patients with depression and insomnia disorder.Methods A total of 120 patients with depression and insomnia admitted to Ningxia Hui Autonomous Region Ning'an Hospital from January 2021 to December were selected and divided into control group(60 cases)and experimental group(60 cases).In addition to conventional antidepressant therapy with paroxetine hydrochloride,the experimental group and the control group were treated with agomelatine and eszopiclone for 8 weeks,respectively.The Hamilton Depression Scale(HAMD)was used to assess the degree of depression in the patients.The Pittsburgh sleep quality index(PSQI)was used to assess the sleep quality of the patients.The enzyme-linked immunosorbent assay was used to detect melatonin and superoxide dismutation enzyme(SOD),brain-derived neurotrophic factor(BDNF)levels.Electrochemiluminescence immunoassay was applied to detect norepinephrine(NE),Dopamine(DA),5-hydroxytryptamine(5-HT)levels.The effects of the two groups after treatment were compared.Results After treatment,compared with the control group,the scores of HAMD and PSQI in the experimental group were decreased(P all＜0.05)and the levels of melatonin,SOD,BDNF,NE,DA and 5-H T were increased(P all＜0.05).Conclusion The combination of agomelatine tablets and paroxetine dydrochloride can significantly improve the degree of depression and sleep quality in patients with insomnia,increase melatonin levels,inhibit oxidative stress,upregulate BDNF levels,and improve neurotransmitter levels.
depression with insomnia disorderagomelatine tabletssuperoxide dismutasebrain-derived neurotrophic factor
万方数据
维普
